SCHEMBL5771980

SCHEMBL5771980

COCCOc1cc(OC)cc(F)c1C#N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SQOR Q9Y6N5 1/20 0.38
TAAR1 Q96RJ0 1/20 0.37
AR P10275 2/20 0.36
ALDH1A1 P00352 4/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
FDPS P14324 1/20 0.35
MAPK8 P45983 1/20 0.35
MAPK9 P45984 1/20 0.35
MAPK10 P53779 1/20 0.35
KDM4E B2RXH2 2/20 0.34
GBA1 P04062 1/20 0.34
HPGD P15428 1/20 0.34
PRKACA P17612 1/20 0.34
PRKACG P22612 1/20 0.34
PRKACB P22694 1/20 0.34
SRC P12931 2/20 0.33
HTT P42858 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20546963 0.82 TRPV4 (0.42) SQORARALDH1A1HSD17B10KDM4E
SCHEMBL6946098 0.82 ALDH1A1 (0.40) SQORTAAR1ARALDH1A1CYP1A2
SCHEMBL5777686 0.82 MAPK8 (0.43) ARALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL186585 0.78 TRPV4 (0.52) SQORTAAR1ALDH1A1CYP1A2CYP3A4
SCHEMBL4523979 0.76 TAAR1 (0.40) TAAR1ALDH1A1CYP1A2KDM4EHPGD
SCHEMBL20547011 0.76 SQOR (0.38) SQORARALDH1A1HSD17B10MAPK8
SCHEMBL5774070 0.75 ALDH1A1 (0.36) SQORTAAR1ALDH1A1CYP1A2CYP3A4
SCHEMBL1154627 0.75 SQOR (0.45) SQORARALDH1A1HSD17B10KDM4E
SCHEMBL13049296 0.72 SQOR (0.39) SQORARKDM4ETRPV4MAPT
SCHEMBL13091914 0.71 KDM1A (0.35) TAAR1ALDH1A1CYP2C19KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1483257-B1 QUINAZOLINE COMPOUNDS USEFUL IN THERAPY PFIZER LTD (GB) 2006-09-13 EP disclosed
US-6936619-B2 Cardiovascular disorders; antilipemic agents; sexual disorders PFIZER, INC. (US) 2005-08-30 US disclosed
EP-1483257-A1 QUINAZOLINE COMPOUNDS USEFUL IN THERAPY Pfizer Limited (GB) 2004-12-08 EP disclosed
US-20040029859-A1 Compounds useful in therapy PFIZER INC. 2004-02-12 US disclosed
WO-2003076427-A1 QUINAZOLINE COMPOUNDS USEFUL IN THERAPY PFIZER LIMITED (GB) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029859-A1 Compounds useful in therapy ADRA1D, HSD3B1, PTGER1 SQOR 525/4885TAAR1 723/4885AR 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.